-
Input from surgeons around the world
Wednesday, December 4, 2019“Retinal detachment has always been a dramatic and terrifying experience for the patient and a source of frustration for the surgeon,” writes Relja Zivojnovic in this book’s foreword. Retinal Detachment Surgery and Proliferative Vitreoretinopathy (PVR): From Scleral Buckling to Small Gauge Vitrectomy (Springer), edited by Ulrich Spandau, Zoran Tomic and Diego Ruiz-Casas, tackles this pathology […]
-
First of its kind in imaging study
Wednesday, December 4, 2019“The eye is an approachable part of the brain.” This quotation is the premise on which half of the subject matter of this handbook is based. The other premise, that optical coherence tomography (OCT) can be used to help diagnose causes of reduced visual acuity not only in adults, but also in children and even […]
-
Unlocking the potential of artificial intelligence
Wednesday, December 4, 2019Pearse Keane MD, FRCOphth Ophthalmology is leading the way in unlocking the potential of artificial intelligence (AI) in the medical arena, and AI will very soon revolutionise the way patients are diagnosed and treated, according to one of the pioneers in the field. Pearse Keane MD, FRCOphth, Consultant Ophthalmologist at Moorfields Eye Hospital, UK, has […]
-
A vision for the future
Wednesday, December 4, 2019Fresh from another record-breaking annual congress in Paris, the European Society of Retina Specialists will be ramping up its efforts to promote science, research and education in the field of retina over the next few years,
-
Gene Therapy Progress
Wednesday, December 4, 2019Optimism for studies of gene therapy of choroideremia and X-linked retinitis pigmentosa.
-
Shoot first, ask questions later
Friday, November 1, 2019Earlier injection recommended in suspected bacterial endophthalmitis
-
Ophthalmologica highlights
Friday, November 1, 2019Aflibercept effective in retinal angiomatous proliferation In eyes with retinal angiomatous proliferation (RAP), an aggressive subtype of neovascular age-related macular degeneration (nAMD), aflibercept produces outcomes comparable to those reported in eyes with type 1 and type 2 nAMD in the pivotal VIEW Study. The patients in the 96-week trial followed the same treatment protocol as […]
-
Endophthalmitis rates increasing
Friday, November 1, 2019Modern vitrectomy techniques improving results in acute endophthalmitis
-
Gut reaction
Tuesday, October 1, 2019Poor nutrition may be contributing to poor ocular health
-
Ophthalmologica highlights
Tuesday, October 1, 2019Vol: 242 Issue: 3
